In a report published Tuesday, Bank of America analyst Bryan D. Spillane initiated coverage on Enzymotec Ltd. ENZY with a Buy rating and $21.00 price target.
In the report, Bank of America noted, “We are initiating coverage of Enzymotec (ENZY) with a Buy rating and $21 PO. In our view, ENZY offers investors attractive growth potential due its exposure to the large and growing consumer health and wellness end markets. Its positioning as a nutritional ingredients and medical foods company with clinically-validated products places the company on the frontier of functional foods where consumers are searching for solutions to medical concerns and preventative care.”
Enzymotec Ltd. closed on Monday at $17.81.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in